Tomčová, Z.; Obertová, J.; Chovanec, M.; Syčová-Milá, Z.; Štefániková, K.; Šlachtová, E.; Žák, M.; Savka, A.; Hrnčár, M.; Rejleková, K.;
et al. Prognostic Value of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab. Biomedicines 2025, 13, 484.
https://doi.org/10.3390/biomedicines13020484
AMA Style
Tomčová Z, Obertová J, Chovanec M, Syčová-Milá Z, Štefániková K, Šlachtová E, Žák M, Savka A, Hrnčár M, Rejleková K,
et al. Prognostic Value of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab. Biomedicines. 2025; 13(2):484.
https://doi.org/10.3390/biomedicines13020484
Chicago/Turabian Style
Tomčová, Zuzana, Jana Obertová, Michal Chovanec, Zuzana Syčová-Milá, Katarína Štefániková, Eva Šlachtová, Monika Žák, Alexander Savka, Matej Hrnčár, Katarína Rejleková,
and et al. 2025. "Prognostic Value of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab" Biomedicines 13, no. 2: 484.
https://doi.org/10.3390/biomedicines13020484
APA Style
Tomčová, Z., Obertová, J., Chovanec, M., Syčová-Milá, Z., Štefániková, K., Šlachtová, E., Žák, M., Savka, A., Hrnčár, M., Rejleková, K., & Palacka, P.
(2025). Prognostic Value of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab. Biomedicines, 13(2), 484.
https://doi.org/10.3390/biomedicines13020484
